Product image of Memolan Initial (Memantine Hydrochloride) supplied by GNH India

Memolan Initial

Active Ingredient:
Memantine Hydrochloride
Origin:
EU

Memolan Initial (Memantine Hydrochloride)

Memantine Hydrochloride, the active ingredient in Memolan Initial, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults.
GNH India supplies Memolan Initial as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

G.L. Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Memolan Initial, an NMDA receptor antagonist, is used in the management of Alzheimer’s disease and related cognitive disorders.

  • Alzheimer’s disease (moderate to severe): improves cognition, functional abilities and overall daily living activities.
  • Alzheimer’s disease (mild to moderate) combined with a cholinesterase inhibitor: provides additional symptomatic benefit.
  • Behavioral symptoms in Alzheimer’s disease: may reduce agitation and improve patient cooperation.

How It Works

  • Memantine Hydrochloride acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it blocks excessive calcium influx caused by high glutamate levels, thereby reducing excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Side Effects

Adverse reactions to memantine may vary in frequency and severity.

Common Side Effects

  • Dizziness: sensation of light‑headedness or unsteadiness.
  • Headache: mild to moderate cranial pain.
  • Constipation: reduced bowel movements.
  • Confusion: transient mental clouding.
  • Fatigue: feeling unusually tired.
  • Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects

  • Seizures: occurrence of convulsive episodes.
  • Cardiac arrhythmias: irregular heart rhythms requiring medical attention.
  • Severe allergic reactions: rash, swelling, or anaphylaxis.
  • Stevens‑Johnson syndrome: rare but serious skin disorder.

Precautions & Warnings

Before initiating therapy, consider the following safety measures.

  • Renal impairment: assess kidney function and adjust dose if necessary.
  • Cardiovascular disease: monitor blood pressure and heart rhythm regularly.
  • History of seizures: observe for new seizure activity.
  • Concomitant NMDA antagonists: avoid combined use to reduce neurotoxicity risk.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
  • Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Memantine may interact with other medications; review patient regimens carefully.

Major Interactions (Avoid)

  • Amantadine: additive NMDA antagonism may increase toxicity.
  • Ketamine: combined NMDA blockade can lead to excessive CNS effects.
  • Other NMDA antagonists: heightened risk of neurotoxicity.

Moderate Interactions (Monitor Closely)

  • Diuretics: may raise plasma memantine concentrations.
  • Anticholinergics: could worsen cognitive impairment.
  • CNS depressants: may enhance dizziness or sedation.

Frequently Asked Questions

Memolan Initial contains memantine hydrochloride and is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease. It helps improve cognitive function, daily living activities, and may reduce behavioral disturbances in affected patients.

Memantine is a non‑competitive antagonist of the NMDA receptor. By blocking the receptor’s ion channel, it limits excessive calcium influx caused by high glutamate levels, thereby reducing excitotoxic neuronal damage that contributes to the progression of Alzheimer’s disease.

The dosing regimen for memantine is individualized. A qualified prescriber determines the appropriate dose based on the patient’s clinical condition, renal function, and response, following the approved labeling and clinical guidelines.

Safety of memantine in pregnancy and lactation has not been established. It is classified as a pregnancy category of unknown risk, and use should be considered only when the potential therapeutic benefit justifies any possible risk to the fetus or infant.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas drugs such as donepezil are cholinesterase inhibitors. Memantine is typically used in moderate to severe disease stages and may be combined with a cholinesterase inhibitor for added benefit, while cholinesterase inhibitors are often first‑line for mild to moderate disease.

Store Memolan Initial at room temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Memolan Initial is taken orally. Swallow the tablet whole with a glass of water; it may be taken with or without food. Follow the prescriber’s instructions regarding timing and any dose adjustments.

Serious adverse events, although rare, include seizures, cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Memolan Initial should be avoided in patients with known hypersensitivity to memantine or any of its excipients, in those with severe renal impairment without appropriate dose adjustment, and in individuals taking other NMDA antagonists that could increase neurotoxicity.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Memantine Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT